NSAIDs-COX-2 Inhibitors-Risks and Benefits

Pharmacovigilance: Second Edition

Volumn , Issue , 2007, Pages 583-602

  Chan, K Arnold ^a,b   Jones, S Christopher ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b US Food and Drug Administration ^*

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cardioprotective effects of naproxen; Cardiovascular safety signal evaluation; COX 2 inhibitors and colorectal adenoma prevention; Non steroidal anti inflammatory drugs (NSAIDs) and COX 2 inhibitors; Post marketing cardiovascular safety signal

Indexed keywords

EID: 84889354882     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059210.ch47     Document Type: Chapter

References (63)

1. Aldington S, Shirtcliffe P, Weatherall M et al. (2005) Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. New Zealand Medical Journal, 118, 1684-9.
2. Andersohn F, Schade R, Suissa S et al. (2006) Cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs and the risk of ischemic stroke: A nested case-control study. Stroke, 37, 1725-30.
3. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 308, 81-106 [Erratum, BMJ, 308, 1540].
4. Arber N, Eagle CJ, Spicak J et al., for the PreSAP Trial Investigators (2006) Celecoxib for the prevention of colorectal adenomatous polyps. New England Journal of Medicine, 355, 885-95.
5. Aw TJ, Haas SJ, Kiew D et al. (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Archives of Internal Medicine, 165, 490-6.
6. Bertagnolli MM, Eagle CJ, Zauber AG et al., for the APC Study Investigators (2006) Celecoxib for the prevention of sporadic colorectal adenomas. New England Journal of Medicine, 355, 873-84.
7. Bombardier C, Laine L, Reicin A et al., for the VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 343, 1520-8.
8. Bresalier RS, Sandler RS, Quan H et al., for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine, 352, 1092-102 Correction (2006) 355, 221.
9. Cleveland Clinic press release (2005) Cleveland Clinic launches large-scale global trial to examine cardiovascular safety of popular pain relievers. December 13, 2005. http://www.clevelandclinic.org/heartcenter/pub/news/archive/2005/painrelief12_13.asp.
10. Curfman GD, Morrissey S and Drazen JM (2005) Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000; 343: 1520-8. New England Journal of Medicine, 353, 2813-14.
11. Edwards IR (2005) What are the real lessons from Vioxx? Drug Safety, 28, 651-8.
12. Farkouh ME, Kirshner H, Harrington RA et al., on behalf of the TARGET Study Group (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet, 364, 675-84.
13. FDA Arthritis Committee meeting briefing information (2001) February 7 and 8, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm and http://www. fda.gov/ohrms/dockets/ac/01/briefing/3677b2.htm.
14. FitzGerald GA (2003) COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Review of Drug Discovery, 2, 879-90.
15. FitzGerald GA (2004) Coxibs and cardiovascular disease. New England Journal of Medicine, 351, 1709-11.
16. Gislason GH, Jacobsen S, Rasmussen JN et al. (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation, 113, 2906-13.
17. Graham DJ, Campen D, Hui R et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet, 365, 475-81.
18. Hippisley-Cox J and Coupland C (2005) Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ, 330, 1366-72.
19. Hrachovec JB and Mora M (2001) Reporting of 6-month vs 12-month data in a clinical trial and celecoxib. JAMA, 286, 2398-400.
20. Huang W-F, Hsiao F-Y, Tsai Y-W et al. (2006) Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: An observational study. Drug Safety, 29, 261-72.
21. Johnsen SP, Larsson H, Tarone RE et al. (2005) Risk of hospitalisation for myocardial infarction among users of rofecoxib, celecoxib and other NSAIDs: a population based case control study. Archives of Internal Medicine, 165, 978-84.
22. Jüni P, Nartey L, Reichenbach S et al. (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet, 364, 2021-9.
23. Kearney PM, Baigent C, Godwin J et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332, 1302-8.
24. Kimmel SE, Berlin JA, Reilly M et al. (2005) Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Annals of Internal Medicine, 142, 157-64.
25. Konstam MA, Weir MR, Reicin R et al. (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 104, 2280-8.
26. Kweder S (2004) Statement before Committee on Finance, United States Senate, November 18, 2004. http://www.fda.gov/ola/2004/vioxx1118.html.
27. La Grenade L, Lee L, Weaver J et al. (2005) Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Safety, 28, 917-24.
28. Lagakos SW (2006) Time-to-event analyses for long-term treatments-The APPROVe Trial. New England Journal Medicine, 355, 113-17.
29. Layton D, Heeley E, Hughes K et al. (2003a) Comparison of the incidence rates for thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology, 42, 1342-53.
30. Layton D, Hughes K, Harris S et al. (2003b) Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology, 42, 1354-64.
31. Levesque LE, Brophy JM and Zhang B (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Annals of Internal Medicine, 142, 481-9.
32. Levin B (2005) Celecoxib in adenoma prevention-the PreSAP trial. Presentation at FDA advisory committee meeting, February 16, 2005. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4090S1_09_FDA-Levin_files/frame.htm.
33. Mamdani M, Rochon P, Juurlink DN et al. (2003) Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of Internal Medicine, 163, 481-6.
34. Mamdani M, Juurlink DN, Lee DS et al. (2004) Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet, 363, 1751-6.
35. Matchaba P, Gitton X, Krammer G et al. (2005) Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clinical Therapeutics, 27, 1196-214.
36. McGettigan P, Han P and Henry D (2006) Cyclooxygenase-2 inhibitors and coronary occlusion: exploring dose-response relationships. British Journal of Clinical Pharmacology, 62, 358-65.
37. McGettigan P and Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 296, released online on September 12, 2006. http://jama.amaassn.org/cgi/reprint/296.13.jrv60011v1.
38. Merck Press Release (2006) Merck provides preliminary analyses of the completed MEDAL program for ARCOXIA™ (Etoricoxib). http://www.merck.com/newsroom/press_releases/research_and_development/2006_0823.html
39. Mukherjee D, Nissen SE and Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286, 954-9.
40. NIH news release (2004) Use of non-steroidal antiinflammatory drugs suspended in large Alzheimer's disease prevention trial. NIH Office of Communication, December 20, 2004. http://www.nih.gov/news/pr/dec2004/od-20.htm.
41. Nussmeier NA, Whelton AA, Brown MT et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal Medicine, 352, 1081-91.
42. Ott E, Nussmeier NA, Duke PC et al., Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 125, 1481-92.
43. Ray WA, Stein CM, Daugherty JR et al. (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet, 360, 1071-3.
44. Ray WA and Stein CM (2006) Reform of drug regulation-beyond an independent drug-safety board. New England Journal Medicine, 354, 194-201.
45. Reicin A, Shapiro D, Sperling RS et al. (2002) Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with Rofecoxib vs nonselective non-steroidal antiinflammatory drugs (ibuprofen, diclofenac and nabumetone). American Journal of Cardiology, 89, 204-9.
46. Schiffenbauer J (2005) Analysis of cardiovascular thromboembolic events with etoricoxib. Presentation at FDA advisory committee meeting, February 16, 2005. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4090S2_04_FDA-Schiffenbauer.htm
47. Schnitzer TJ, Burmester GR, Mysler E et al., on behalf of the TARGET Study Group (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet, 364, 665-74.
48. Shaya FT, Blume SW, Blanchette CM et al. (2005) Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Archives of Internal Medicine, 165, 181-6.
49. Silverstein FE, Faich G, Goldstein JL et al. (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA, 284, 1247-55.
50. Solomon DH, Schneeweiss S, Glynn RJ et al. (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 109, 2068-73.
51. Solomon SD, McMurray JJV, Pfeffer MA et al., for the Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine, 352, 1071-80.
52. Solomon SD, Pfeffer MA, McMurray JJV et al., for the APC and PreSAP Trial Investigators (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114, 1028-35.
53. Strom BL (2006) How the US Drug Safety System should be changed. JAMA, 295, 2072-4.
54. Van Hecken A, Schwartz JI, Depre M et al. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. Journal of Clinical Pharmacology, 40, 1109-20.
55. Velentgas P, West W, Cannuscio CC et al. (2006) Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiology and Drug Safety, 15, 641-52.
56. Warner TD, Giuliano F, Vojnovic I et al. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of National Academy of Science USA, 96, 7563-8.
57. Weir MR, Sperling RS, Reicin A et al. (2003) Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. American Heart Journal, 146, 591-604.
58. Whelton A, White WB, Bello AE et al., and the SUCCESSVII Investigators (2002) Effects of celecoxib and rofecoxib on blood pressure and edema in patients >65 Years of age With systemic hypertension and osteoarthritis. American Journal of Cardiology, 90, 959-63.
59. White WB, Faich G, Whelton A et al. (2002) Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. American Journal of Cardiology, 89, 425-30.
60. White WB, Faich G, Borer JS et al. (2003) Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase2 inhibitor celecoxib. American Journal of Cardiology, 92, 411-18.
61. White WB, Strand V, Roberts R et al. (2004) Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. American Journal of Therapeutics, 11, 244-50.
62. Wolfe MM, Lichtenstein DR and Singh G (1999) Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. New England Journal of Medicine, 340, 1888-99.
63. Zhang J, Ding EL and Song Y (2006) Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events meta-analysis of randomized trials. JAMA, 296, released online on September 12, 2006. http://jama.amaassn.org/cgi/reprint/296.13.jrv60015v1.